Novartis's antipsychotic Fanapt launched in the US
12 January 2010
Katie McQue
Please Login to read the full article.
12 January 2010
Katie McQue
katie.mcque@informa.com
Novartis has launched its twice daily oral atypical antipsychotic Fanapt (iloperidone) in the US for the treatment of acute treatment of schizophrenia in adults.
Fanapt was approved by the US
FDA in May, after it was filed by Vanda Pharmaceuticals. Vanda was originally set to commercialise...
Please Login to read the full article.
RELATED CONTENT
NEWS
- First Phase III signs positive for cariprazine in bipolar mania
- Vanda, Megapharm in deal for schizophrenia drug Fanapt in Israel
- Alexza blows up on FDA concerns over lung risks with inhaled antipsychotic
- Zogenix, Duract in deal for work on once-monthly risperidone, to contrast with J&J blockbuster
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
